Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) chief executive Jeremy Skillington speaks to Proactive after researchers identified "multiple" potential drug targets for respiratory syncytial virus (RSV) using artificial intelligence.
AI technology developed by OneThree Biotech was used to "interrogate" the large bank of RSV human challenge data held by Poolbeg.
Skillington says that the breakthrough makes this a "very exciting time for the company" and expects the collaboration to continue bearing fruit, particularly because RSV is "rampant" and affects "up to 50mln people a year."